Sectors
SMMT
Summit Therapeutics Inc.
19.38
24 x 19.09
24 x 19.77
bid
ask
+
0.46
2.43%
24 @ 04:00 PM
19.34 -0.04 (0.21%)
Ytd 10.81%
1y -5.28%
18.40
day range
19.85
13.85
52 week range
36.70
Open 18.41 Prev Close 18.92 Low 18.40 High 19.85 Mkt Cap 15.03B
Vol 3.08M Avg Vol 2.73M EPS -1.44 P/E N/A Forward P/E -16.78
Beta -1.39 Short Ratio 17.16 Inst. Own 15.50% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 04-30 50-d Avg 15.90 200-d Avg 19.84 1yr Est 29.15
Earning
Date For Estimate Reported Surprise surprise %
2026-05-07 2026-03 0 N/A N/A N/A
2026-02-23 2025-12 0 N/A -0.07 -31.82%
2025-10-20 2025-09 0 N/A -0.17 -121.43%
2025-08-11 2025-06 0 N/A -0.66 -660.00%
2025-05-01 2025-03 0 N/A 0.01 10.00%
2025-02-24 2024-12 0 N/A N/A N/A
Upgrade / Downgrade
Date Firm Action From To
2026-03-16 Jefferies Downgrade Buy Hold
2026-02-24 HC Wainwright & Co. Upgrade Buy Buy
2026-02-02 HC Wainwright & Co. Upgrade Buy Buy
2026-01-30 Citizens Upgrade Market Outperform Market Outperform
2025-12-17 Barclays Upgrade Underweight Equal-Weight
2025-11-18 Wolfe Research Upgrade Peer Perform
Profile
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Insider Holder
Date Name Relation Quantity Description
2025-10-20 ANAND BHASKAR Officer 159.75K Stock Award(Grant)
2025-10-20 DUGGAN ROBERT WILLIAM Chief Executive Officer 0.00 Stock Award(Grant)
2024-09-10 HUBER JEFFREY T Director 0.00 Stock Award(Grant)
2025-10-20 SONI MANMEET SINGH Chief Operating Officer 3.07M Stock Award(Grant)
2025-10-20 XIA YU Director 0.00 Purchase
2025-10-20 ZANGANEH MAHKAM Chief Executive Officer 0.00 Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Baker Bros. Advisors, LP 36.39M 705.26M 4.69%
2025-12-30 FMR, LLC 13.36M 258.93M 1.72%
2025-12-30 Vanguard Group Inc 11.18M 216.61M 1.44%
2025-12-30 Blackrock Inc. 9.36M 181.43M 1.21%
2025-12-30 Price (T.Rowe) Associates Inc 9.37M 181.62M 1.21%
2025-12-30 State Street Corporation 6.64M 128.61M 0.86%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 T. Rowe Price Health Sciences Fund, Inc. 7.29M 141.21M 0.94%
2026-01-30 SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF 4.97M 96.28M 0.64%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 3.53M 68.38M 0.46%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund 2.54M 49.18M 0.33%
2026-02-27 Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund 2.38M 46.18M 0.31%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund 1.63M 31.66M 0.21%